 The New Zealand Medicines and Medical Devices Safety Authority MEDSAFE has signed off Intellia Therapeutics Incs NASDAQ: NTLA Phase 12 study of NTLA-2002 in hereditary angioedema HAE. NTLA-2002 is a systemically administered single-dose CRISPR Cas9-based therapeutic candidate designed to inactivate the target gene Kallikrein B1 KLKB1 to reduce plasma kallikrein activity and thus prevent HAE attacks. 